Jean Lachaine

Dr. Jean Lachaine

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
JLJean Lachaine
Jean Lachaine
CBCatherine Beauchemin
Catherine Beauchemin
PLPierre-Alexandre Landry
Pierre-Alexandre Landry
Fibromyalgia syndrome (FMS) is a chronic disorder defined by widespread muscle pain and multiple tender points. The objectives of this study were to estimate prevalence of comorbidities, healthcare resources utilization, and costs associated with FMS. A retrospective cohort study was conducted using data from the Quebec provincial health plans (RAMQ) for a random sample of patients with diagnoses of FMS and a control cohort of patients without FMS, matched for age and gender. Prevalence of comorbidities was estimated. Healthcare resources consumed by FMS and non-FMS patients were identified in terms of visits to physicians, physician's interventions, pain-related medications, nonpain-related medications, and hospitalizations. A total of 16,010 patients with 2 diagnoses of FMS were identified, and control patients were randomly selected with a ratio of 1:1. Incidence of most comorbidities was significantly higher in the FMS group and the chronic disease score (3.8 vs. 2.8; ANOVA P <0.001). The proportion of patients with at least 1 comorbidity was 87.4% in the FMS group and 60.1% in the control group (chiP<0.001). The annual number of visits to physician and physician's interventions was 25.1 for FMS and 14.8 for non-FMS patients. The amount paid by the RAMQ was significantly higher for patients with FMS ($4065) compared with patients without FMS ($2766) (ANOVA P<0.001). Results of this analysis of the RAMQ database illustrate the high prevalence of comorbidities among patients with a diagnosis of FMS and strongly indicate that the economic burden of FMS is substantial.

30 January 2013 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
JLJean Lachaine
Jean Lachaine
LYLinnette Yen
Linnette Yen
CBCatherine Beauchemin
Catherine Beauchemin
PHPaul Hodgkins
Paul Hodgkins
Although high non-adherence to medication has been noticed for ulcerative colitis (UC), little is known about adherence to mesalamine treatments and determinants that can predict adherence. The objective of this study was to assess adherence and persistence to mesalamine treatments and their potential determinants in mild to moderate UC patients in a real-life setting in Quebec, Canada.

1 May 2012 in Postgraduate Medicine
Verified
Journal Article
Closed access
JLJean Lachaine
Jean Lachaine
CBCatherine Beauchemin
Catherine Beauchemin
RSRahul Sasane
Rahul Sasane
PHPaul S. Hodgkins
Paul S. Hodgkins
Objective: To understand attention–deficit/hyperactivity disorder (ADHD) treatment patterns and estimate adherence and persistence in Quebec, Canada. Design: This cross–sectional, retrospective prescription claims analysis used a random sample of 15 838 patients with ADHD from a Quebec database (Régie de l'assurance maladie du Québec [RAMQ]) to assess treatment patterns, adherence (1–year medication possession ratio in new users), and persistence (proportion persistent at 3, 6, and 12 months after index prescription). Results: The mean patient age was 14 years; 72.6% were male. During the 5–year study period (2004–2009), 416 646 ADHD prescriptions were flled. Short–acting (SA) medications declined from 72.8% to 26.4% of all claims, while stimulant and nonstimulant long–acting (LA) medications increased from 27.2% to 73.6%. Approximately half of the patients used both SA and LA medications (either concomitantly or subsequently), and the others used only SA (30%) or LA (19%) drugs. Among patients us...

20 May 2011 in BMC Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JLJean Lachaine
Jean Lachaine
CBCatherine Beauchemin
Catherine Beauchemin
ERElodie Ramos
Elodie Ramos
Risk of morbidity and mortality in patients with severe heart failure (HF) is reduced by blockade of aldosterone receptors with spironolactone. However, benefits of spironolactone are potentially limited by treatment compliance and adverse events profile. The aim of this study was to estimate use of spironolactone by patients with HF, incidence of key adverse events, and patient compliance.

1 January 2007 in Pain Research and Management
Verified
Journal Article
Open access
PDF file
JLJean Lachaine
Jean Lachaine
AGA Gordon
A Gordon
MCM Choinière
M Choinière
JCJp Collet
Jp Collet
DDD Dion
D Dion
JTJ-E Tarride
J-E Tarride
BACKGROUND/OBJECTIVE: Painful neuropathic disorders (PNDs) refer to neurological disorders involving nerves in which pain is a predominant symptom. In most cases, PNDs involve the peripheral nerves. Treatment of PNDs is likely to use large health care resources. However, little is known about the economic burden of PNDs in Canada.METHOD: The present study was performed using data from a random sample of patients covered by the Régie de l’Assurance Maladie du Quebec drug plan. Subjects with a diagnosis of a peripheral PND were identified. Comorbidities, pain‐related medication use and resource utilization were compared between PND patients and control patients without PNDs matched for age and sex in a 1:1 ratio.RESULTS: A total of 4912 patients with PNDs were identified. A higher level of comorbidities was found in the PND group (Von Korff chronic disease score 3.91 versus 2.54; P<0.001). The proportion of users of pain‐related medications was significantly higher in the PND cohort than in the control group (χ2; P<0.001). The average annual number of physician visits was also significantly higher in the PND group than in the control group (14.7 versus 6.4; P<0.001). From a health ministry perspective, costs of health care resources were significantly higher in the PND group ($4,163 versus $1,846; P<0.001). The proportion of potentially inappropriate medications was 34% among those 65 years of age or older.CONCLUSIONS: PNDs are associated with a higher level of comorbidities, higher medical resources utilization and higher health care costs than non‐PND conditions.

1 July 2006 in American Heart Journal
Verified
Journal Article
Closed access
JLJean Lachaine
Jean Lachaine
SRStephane Rinfret
Stephane Rinfret
EMElizabeth P. Merikle
Elizabeth P. Merikle
JTJean-Eric Tarride
Jean-Eric Tarride